Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis

Table 3

OX40 and OX40L expression in patients with MG at different stages.

Group	Membrane-bound molecules				Soluble molecules
	No.	CD4^+OX40 (%)	CD19^+OX40L^+ (%)	CD14^+OX40L^+ (%)	No.	sOX40 (pg/ml)	sOX40L (ng/ml)
Baseline	39	6.20 (3.48, 9.43)^a,b	67.30 (57.45, 74.25)^a,b	82.00 (78.35, 89.75)^a,b	37	^a,b	^a.b
Remission	42	4.85 (3.17, 7.47)^c	69.35 (60.00, 78.20)^c	83.85 (78.30, 90.00)^c	30	^c	^c
Relapse	22	13.15 (6.00, 15.50)	67.30 (60.20, 74.80)	88.90 (77.60, 93.00)	34
a		,	,	,
b		,	,	,
c		,	,	,

a: baseline vs. remission; b: baseline vs. relapse; c: remission vs. relapse.